## A: Agilent Technologies, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -5.4% below STRENGTH zone (3.0-6.0%); PEG 2.16 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-3.4% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($137.23)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 5, Bearish: 0)

**1. Jim Cramer on Agilent: “The Thing’s Just Caught Fire”**
- Source: Insider Monkey | 20251204T120500 | Bullish | Relevance: 100%
- Jim Cramer highlighted Agilent Technologies (NYSE:A) as a company whose stock has recently "caught fire," rising over 55% from its April lows. He noted that the life sciences industry, including Agilent, faced challenges post-pandemic but is now seeing a turnaround driven by reshoring in manufacturing and new medical advancements. Cramer found CEO Padraig McDonnell's interview encouraging, citing a solid quarter with 7% organic growth.

**2. Jim Cramer on Agilent: "The Thing's Just Caught Fire"**
- Source: Finviz | 20251204T120500 | Bullish | Relevance: 99%
- Jim Cramer highlighted Agilent Technologies (NYSE: A) as a stock that has "caught fire," despite a period of choppiness for the life sciences industry post-pandemic. He noted the company's 55% surge from April lows, a solid quarter with 7% organic growth, and encouraging signs of a business turnaround driven by reshoring in life sciences manufacturing and novel medicine requirements. Cramer also mentioned that the Trump FDA under RFK Jr. has been less disruptive than expected on Wall Street.

**3. Morgan Stanley Initiates Coverage on Agilent Technologies (NYSE:A)**
- Source: MarketBeat | 20251203T141550 | Bullish | Relevance: 99%
-  Morgan Stanley initiated coverage on Agilent Technologies (NYSE:A) with an "overweight" rating. This report details recent analyst ratings, stock performance, and insider transactions for Agilent Technologies, highlighting several "buy" and "outperform" ratings from other firms. The company's financial health, including its market cap, P/E ratio, and recent earnings, are also covered.

**4. Agilent and Monash University Malaysia Mark 15-Year Partnership with New BioDiscovery Hub to Drive Regional Biotech Innovation**
- Source: PR Newswire | 20251205T093000 | Bullish | Relevance: 99%
- Agilent Technologies Inc. expanded its strategic collaboration with Monash University Malaysia to establish a new MUMPMP-Agilent BioDiscovery Hub. This initiative, marked by a 15-year partnership celebration, aims to accelerate regional biotechnology research and innovation, focusing on small- and large-molecule analysis. The BioDiscovery Hub will deploy Agilent's advanced analytical instrumentation to support research programs, application development, and scientific training, reinforcing Malaysia's role as a biotech innovation hub.

**5. Agilent Technologies (NYSE: A) director reports sale of 2,600 shares**
- Source: Stock Titan | 20251203T210400 | Neutral | Relevance: 98%
- A director of Agilent Technologies, Inc. (NYSE: A) reported the sale of 2,600 shares of common stock on December 1, 2025, at a weighted average price of $149.812 per share. Following this transaction, the director beneficially owns 4,973.028 shares of Agilent common stock, which includes shares acquired through a dividend reinvestment plan. The transaction was disclosed in a Form 4 filing with the SEC.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 7, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Goldman Sachs | $170 | $0 | 0% |
| 2025-12-02 | Morgan Stanley | $180 | $0 | 0% |
| 2025-11-25 | Citigroup | $185 | $165 | +12% |
| 2025-11-25 | UBS | $180 | $170 | +6% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Goldman Sachs | init | Buy |
| 2025-12-02 | Morgan Stanley | init | Overweight |
| 2025-11-25 | Citigroup | main | Buy |
| 2025-11-25 | UBS | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 10 ($1.37M) |
| Sells | 18 ($1.60M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 44.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.0% (+0.1%)
- Blackrock Inc.: 9.2% (+1.0%)
- Massachusetts Financ: 4.4% (-6.0%)
- State Street Corpora: 4.4% (-0.1%)
- Wellington Managemen: 3.3% (+4.8%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-3.4% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 7 raises (avg +12%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 2.16 elevated, pricing in significant growth expectations. Forward P/E 22.2x stretched relative to 10% growth. Quality metrics strong (ROE 21%, margin 19%). Analyst sentiment positive (7 raises, avg +12%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $39.9B |
| Beta | 1.27 |
| 52W Range | $96.43 - $160.27 |
| Short Interest | 1.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.16 |
| Forward P/E | 22.2 |
| Current P/E | 24.5 |
| YoY Growth | 10.3% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from -1.9% to -5.4% (-3.4% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 8.4pp (needs >3.0% for momentum thesis). Underperforming sector by 3.0pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.17x) but short-term weakness (below SMA20). MACD histogram bearish (-0.80), momentum weakening. RSI neutral at 46.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -5.36% (CS: 5) | Weak |
| RSI_14 | 46.0 | Neutral |
| MACD Histogram | -0.80 | Bearish |
| vs SMA20 | 0.977x | Below |
| vs SMA50 | 1.009x | Above |
| vs SMA200 | 1.174x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $145.49
- **Stop Loss:** $137.23 (5.7% risk)
- **Target:** $153.75 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 60
- **Position Value:** $8,729.40
- **Portfolio %:** 8.73%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with moderate risk appetite persisting. Mixed earnings signals with industrial weakness (John Deere) offset by consumer/tech strength, while institutional flows show selective positioning rather than broad risk-off. Fed meeting in 9 days provides near-term catalyst but current data suggests status quo maintenance.*

### Earnings

**Next:** 2026-02-25 (Est: $1.37)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q4 | $1.58 | $1.59 | +0.4% |
| 2025Q3 | $1.37 | $1.37 | +0.2% |
| 2025Q2 | $1.26 | $1.31 | +3.6% |
| 2025Q1 | $1.27 | $1.31 | +3.0% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*